The overall contribution of Nav1.7 to pain in some animal behaviour-based models has been questioned (Shields et al., 2018), whereas research and development of multiple potent and selective Nav1.7 inhibitors have failed to recapitulate the pain-free state that characterized CIP in humans (Eagles et al., 2020). Here, SCN9A is linked to hereditary sensory and autonomic neuropathy.